Pharmaceutical - Immunologicals, Research

Filter

Current filters:

ImmunologicalsResearch

Popular Filters

1 to 25 of 42 results

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

Stallergenes links with ActoGeniX on new class of oral allergy treatments

03-12-2013

French allergen specialist Stallergenes and ActoGeniX NV, creator of ActoBiotics, have entered into an…

ActoBioticsActoGeniXImmunologicalsLicensingPharmaceuticalResearchStallergenes

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

Pfizer says Rapamune failed endpoints in renal transplant study

Pfizer says Rapamune failed endpoints in renal transplant study

09-11-2013

US pharma behemoth Pfizer released disappointing top-line results from a Phase IIIb/IV study of its already-marketed…

ImmunologicalsPfizerPharmaceuticalRapamuneResearch

Stallergenes and DBV Technologies collaborate in birch pollen allergy research

18-10-2013

French allergy specialists Stallergenes and DBV Technologies, creator of Viaskin for the treatment of…

DBV TechnologiesImmunologicalsPharmaceuticalResearchRespiratory and PulmonaryStallergenes

Novartis links with Regenerex in cell therapy research collaboration

06-09-2013

Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…

BiotechnologyCTL019HSC835ImmunologicalsLicensingNovartisPharmaceuticalRegenerexResearch

Swedish researcher report on unexpected use of former cancer drug

29-08-2013

Researchers at Sweden's Lund University have unexpectedly discovered that an old cancer drug - zebularine…

ImmunologicalsOncologyPharmaceuticalResearchzebularine

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Merck Serono sets up new platform for cancer therapies innovation

26-06-2013

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

Bayer expands collaboration with DKFZ into immunotherapy

10-04-2013

German drug major Bayer (BAYN: DE) said revealed this morning that it will extend if already successful…

BayerImmunologicalsOncologyPharmaceuticalResearch

Ben-Gurion University researchers and Teva develop psoriasis drug

21-03-2013

Researchers at Ben-Gurion University of the Negev (BGU), in collaboration with Israel largest drugmaker…

DermatologicalsImmunologicalsPharmaceuticalResearchTeva Pharmaceutical Industries

Merck & Co in new $300 million deal with Lycera

13-02-2013

USA-based drug developer Lycera Corp has announced a new agreement with US pharma giant Merck & CO (NYSE:…

ImmunologicalsLicensingLycera CorpMerck & CoPharmaceuticalResearch

Sanofi inks up to $900 million allergy pact with Selecta Biosciences

28-11-2012

US clinical-stage biopharma company Selecta Biosciences revealed this morning that it has entered into…

BiotechnologyImmunologicalsLicensingPharmaceuticalResearchSanofiSelecta BiosciencesVaccines

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

Belgium's UCB enters third research accord with Harvard University

10-10-2012

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB), says it has launched a third collaborative…

ImmunologicalsPharmaceuticalResearchUCB

1 to 25 of 42 results

Back to top